Foghorn Therapeutics Inc.·4

Jan 30, 5:02 PM ET

Reine Allan 4

4 · Foghorn Therapeutics Inc. · Filed Jan 30, 2023

Insider Transaction Report

Form 4
Period: 2023-01-26
Reine Allan
Chief Financial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2023-01-26+90,00090,000 total
    Exercise: $8.38Exp: 2033-01-25Common Stock (90,000 underlying)
Footnotes (1)
  • [F1]The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT